RISK FACTORS FOR NONCOMPLIANCE WITH ANTIPSYCHOTIC MEDICATION IN LONG-TERM TREATED CHRONIC SCHIZOPHRENIA PATIENTS

被引:1
作者
Krzystanek, Marek [1 ]
Krysta, Krzysztof [1 ]
Janas-Kozik, Malgorzata [2 ,3 ]
Martyniak, Ewa [1 ]
Rybakowski, Janusz [4 ]
机构
[1] Med Univ Silesia, Dept Rehabil Psychiat, Ziolowa 45-47, PL-40635 Katowice, Poland
[2] Med Univ Silesia, Dept Psychiat & Psychotherapy, Dev Age Clin Ward, Katowice, Poland
[3] John Paul II Pediat Ctr, Sosnowiec, Poland
[4] Poznan Univ Med Sci, Dept Adult Psychiat, Poznan, Poland
关键词
schizophrenia; compliance; drug attitude; antipsychotics; long-term treatment; DRUG ATTITUDE; INSIGHT; OUTPATIENTS; ADHERENCE; REMISSION; CRITERIA;
D O I
暂无
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: The attitudes of schizophrenic patients toward medications directly impact the treatment compliance. Although noncompliance represents a serious concern in long-term schizophrenia treatment, a detailed information on the factors that impair compliance is still limited. The present study aims to assess the factors related to noncompliance with antipsychotics agents, in longterm treated chronic paranoid schizophrenia patients. Subjects and methods: Two groups of such patients (total number n=162) were analyzed and compared: 1). patients with symptomatic remission on haloperidol (n=32), clozapine (n=40) or olanzapine (n=45), and 2). drug resistant patients (n=45). The mean duration of the disease was 19.3 years. Results: Altogether, in our patient sample, a better drug attitude was found in the olanzapine and clozapine groups. Our findings have also revealed that worse attitude toward antipsychotics correlated with an earlier onset of schizophrenia, younger patient age, shorter duration of the disease, higher burden of symptoms, treatment with a typical antipsychotics, and higher severity of akathisia. Conclusion: Our results suggest that detecting factors that influence the patient's attitude toward medications might be helpful for designing targeted educational strategies in chronic schizophrenia patients (particularly those with the high risk of noncompliance), and further trials are warranted to explore this topic.
引用
收藏
页码:S543 / S548
页数:6
相关论文
共 17 条
[1]   Remission in schizophrenia: Proposed criteria and rationale for consensus [J].
Andreasen, NC ;
Carpenter, WT ;
Kane, JM ;
Lasser, RA ;
Marder, SR ;
Weinberger, DR .
AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (03) :441-449
[2]   Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS®) in the Swedish COAST-study [J].
Brain, Cecilia ;
Allerby, Katarina ;
Sameby, Birgitta ;
Quinlan, Patrick ;
Joas, Erik ;
Karilampi, Ulla ;
Lindstrom, Eva ;
Eberhard, Jonas ;
Burns, Tom ;
Waern, Margda .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 (12) :1754-1762
[3]  
Chandra Ivatury Sarath, 2014, Indian J Psychol Med, V36, P294, DOI 10.4103/0253-7176.135383
[4]   Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system [J].
Dassa, Daniel ;
Boyer, Laurent ;
Benoit, Michel ;
Bourcet, Stephane ;
Raymondet, Philippe ;
Bottai, Thierry .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2010, 44 (10) :921-928
[5]   Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST) [J].
Gaebel, Wolfgang ;
Riesbeck, Mathias ;
von Wilmsdorff, Martina ;
Burns, Tom ;
Derks, Eske M. ;
Kahn, Rene S. ;
Roessler, Wulf ;
Fleischhacker, W. Wolfgang .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 (05) :310-316
[6]   The relationship between insight and subjective experience in schizophrenia [J].
Kako, Yuki ;
Ito, Koki ;
Hashimoto, Naoki ;
Toyoshima, Kuniyoshi ;
Shimizu, Yusuke ;
Mitsui, Nobuyuki ;
Fujii, Yutaka ;
Tanaka, Teruaki ;
Kusumi, Chiro .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 :1415-1422
[7]  
Krzystanek Marek, 2015, Psychiatr Danub, V27 Suppl 1, pS266
[8]  
Kuroda Naoaki, 2008, Environmental Health and Preventive Medicine, V13, P288, DOI 10.1007/s12199-008-0043-z
[9]   Effectiveness of antipsychotic drugs in patients with chronic schizophrenia [J].
Lieberman, JA ;
Stroup, TS ;
McEvoy, JP ;
Swartz, MS ;
Rosenheck, RA ;
Perkins, DO ;
Keefe, RSE ;
Davis, SM ;
Davis, CE ;
Lebowitz, BD ;
Severe, J ;
Hsiao, JK .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (12) :1209-1223
[10]   Awareness of illness in schizophrenia: Associations with multiple assessments of executive function [J].
Lysaker, Paul H. ;
Whitney, Kriscinda A. ;
Davis, Louanne W. .
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2006, 18 (04) :516-520